Oxelumab
 | This articlerelies largely or entirely on asingle source.(January 2024) |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | OX-40 ligand |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6424H9920N1704O2014S42 |
| Molar mass | 144594.46g·mol−1 |
  (what is this?)(verify) | |
Oxelumabis a human monoclonal antibody designed for the treatment ofasthma.[1]
Oxelumab was developed byGenentechand co-developed byRoche.
References
[edit]- ^"Statement On A Nonproprietary Name Adopted By The USAN Council: Oxelumab"(PDF).American Medical Association.Archived fromthe original(PDF)on 12 May 2013.
 | Thismonoclonal antibody–related article is astub.You can help Wikipedia byexpanding it. |
 | Thisantineoplasticorimmunomodulatorydrugarticle is astub.You can help Wikipedia byexpanding it. |